PRDM9 and cancer: We found correlations between activity of the histone methyltransferase PRC2 and sensitivity to cPLA2α inhibition, and cPLA2α inhibitors showed similar anti-cancer activity to inhibitors of the catalytic component of PRC2, EZH2, suggesting overlapping mechanisms of action.